Kees Been was CEO of Bial Biotech until 2022, after the company acquired Lysosomal Therapeutics Inc (LTI), a biotech company he founded and led since 2013. LTI focused on probing the lysosomal glycosphingolipid metabolism system for new drug targets in neurodegenerative diseases. Specifically, the approach leverages the genetic link between Gaucher’s and Parkinson’s disease (PD) to develop compounds that enhance the lysosomal glucocerebrosidase (GCase) enzyme activity as an entirely new and breakthrough class of agents for the personalized and disease-modifying treatment in “genetic PD”.
Kees was formerly the CEO of EnVivo Pharmaceuticals (FORUM Pharmaceuticals), a neuroscience biotech company, recognized for its broad pipeline of several NCE drug compounds that were tested for cognition improvement in Alzheimer’s and schizophrenia. He spent four years at Biogen, where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.
Kees holds an MBA degree from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering.